Pediatrics

Families often turn to supplementation to ensure that children are getting the necessary nutrients

The exponential rise in death rate is historic, even as adolescent drug use is low.

At the 43rd National Conference on Pediatric Health Care for nurse practitioners in Dallas, Texas, a look at the newest medications for children with attention-deficit/hyperactivity disorder.

A baseline of dosing errors can lead to a framework to improve antibiotic prescribing habits.

Some parents are still hesitant about vaccinating their children.

Can an educational game could be an effective way to improve opioid knowledge and safety for teenagers?

Recent changes in regulations mean that pharmacists are able to administer vaccines to children as young as 3.

Drug allergies can impact what plan of care is developed for an ill child. An investigation discusses what leads to children receiving a penicillin allergy label in their electronic health records.

Multiple pharmaceutical companies are investigating the application of mRNA technology to develop vaccines that treat and prevent multiple conditions, from influenza to cancer and beyond.

A large cohort study offers important data on what factors are frequently tied to severe cases of COVID-19 in the pediatric population.

PCOS prevalence in girls with type 2 diabetes was almost 20%.

The days of blanket mitigation strategies to protect children from COVID-19 are becoming a thing of the past. One model sheds light onto determining when strategies can be relaxed.

Evidence suggests some pharmaceutical excipients in medications may have adverse effects on pediatric patients. Here’s what you should know.

Emerging evidence is changing health care providers’ approach to treating pediatric rheumatic diseases.

This past year has seen several important new drug approvals and labeling updates for children. Here is what you should know.

Pharmacists can help at-risk youth with asthma through the CAReS program, providing school-based asthma care.

Surviving a bout of cancer early in life puts children and teenagers at risk of cancers linked to human papillomavirus (HPV). A phase 2 trial examined how effective a 3-dose series was in providing protection.

Not every vaccine is required, some are just strongly recommended. Here's what to know about 5 recommended vaccines.

During a session at the 2021 American Academy of Pediatrics National Conference & Exhibition research revealed that introduction to common allergy foods early on can be key in decreasing the frequency of development in children.

Ocugen, Inc. has submitted a request to the FDA for emergency use authorization (EUA) of their COVID-19 vaccine candidate for use in children aged 2 to 18 years.

Initial results from the trial indicate it was well-tolerated and promoted a good immune response.

A press briefing from the Infectious Diseases Society of America focused on the concerns raised by the delta variant and its potential impact on schools.

To protect children and staff at schools, the Infectious Diseases Society of America (IDSA) has recommended using multiple science-based approaches to prevent spread in schools.

Ser/dex is a dexmethylphenidate-based prodrug for ADHD in patients 6 years and older.

For children who have either experienced a delay in pertussis vaccination or who haven’t received the recommended number of doses, what is their risk of pertussis? A new study provides answers.

At the virtual Scientific Sessions for the American Diabetes Association, Jennifer Sherr, MD, discussed the findings of a study of the Omnipod 5 automated insulin delivery system in very young children with type 1 diabetes.

There was a marked decline in child and adolescent routine vaccine administration during the COVID-19 pandemic between March and September 2020; these vaccination rates have continued to lag behind.

Viloxazine is a selective norepinephrine reuptake inhibitor and is the first new nonstimulant medication for treatment of ADHD in children in more than 10 years.

The FDA approved Cosentyx (secukinumab) to treat moderate-to-severe plaque psoriasis in children aged 6 years and older.

The company has publicized data from the TeenCOVE study of the vaccine along with plans to seek authorization in the coming weeks.